Pfizer Stock and Biontech Drop on Moderna Supply Concerns as the Leading Distribution of a New Booster Shot

Spread the love

Pfizer stock price was at $44.72, a slight drop on Wednesdays pre-market trading as of 08:20 AM EDT.

More than 25 million doses of the new COVID-19 booster shots have been made available by the U.S. government, largely from Pfizer (NYSE:PFE)/BioNTech (BNTX), while Moderna (NASDAQ:MRNA) is increasing manufacturing.

The government supplies of Modernas (MRNA) revised vaccination were restricted, according to top drugstore retailers Walgreens Boots Alliance Inc. (WBA) and CVS Health Corp. (CVS) on Tuesday. Both businesses said there were no supply problems for the new Pfizer/BioNTech booster and that they were working with the government to obtain more Moderna (MRNA) shots.

The companys upgraded booster shots were produced by contract manufacturer Catalent Inc. (CTLT) at a facility in Bloomington, Indiana, which is not currently allowed to create the updated doses, according to a statement from the FDA on Tuesday. According to the regulator, Moderna (MRNA) asked the FDA to approve the batches in response to the supply problems.

In light of strong demand in some sections of the country, a Moderna (MRNA) representative said on Tuesday that the business is coordinating closely with the American government to ship large numbers of upgraded boosters.

The company is on pace to provide 70 million doses of revised booster shots by the end of the year, according to Moderna (NASDAQ:MRNA), which anticipates that the supply issues will be rectified in the coming days.

Following regulatory approval of the shots intended to combat the original COVID-19 strain and BA.4 and BA.5 Omicron subvariants, the U.S. began rolling out 175 million doses of upgraded boosters at the beginning of this month.

Pfizer, Biontech, Moderna, Novavax To Gain In Passing Of New Law

Pfizer Stock price projection

After U.S. President Joe Biden stated that the COVID-19 epidemic was gone in the country in an interview with 60 Minutes on CBS News over the weekend, the stocks of firms that produce COVID-19 vaccinations and medications fell on Monday.

Stock prices for BioNTech, Moderna, and Novavax fell 8.6%, 7.1%, and 6.5%, respectively. Pfizer, a partner of BioNTech, decreased by roughly 1.3%.

Moderna, BioNTech, and Novavax stocks all fell because once the pandemic is over, their sales and profitability will plummet. This is due to the fact that their sole top-line drivers were COVID-related vaccinations and products. BioNTech and Moderna stocks have increased by about 300% and 400%, respectively, since the pandemic began in March 2020.

Bidens remark actually had a negative impact on Pfizer stock as well because Paxlovid, an antiviral drug and COVID-19 vaccine, generates nearly half of the companys sales. For the following few quarters, Pfizer and Moderna anticipated that their main sources of revenue would come from the updated boosters. The demand for COVID-19 vaccinations and other medications will fall once the epidemic stops, which will negatively impact these companies sales and profitability.

To support their long-term growth, the corporations will eventually need to identify new top-line drivers. Sales of vaccines and medications have resulted in significant inflows of cash for Moderna, Pfizer, and BioNTech. To make up for lost sales of COVID products, they can use the money for more research and successfully create other items.

More on the Zack Analyst blog at Yahoo Finance.

Featured Image – Megapixl (C) Bizoon

Please See Disclaimer

Visit PressReach.com To Get More Articles Like This

Author: Jowi Kwasu
Market Jar Media Inc.
info@marketjar.com
#170 – 422 Richards Street
Vancouver, BC, Canada
V6B 2Z4
1.800.340.9767

comtex tracking

COMTEX_414970715/2814/2022-09-21T12:13:05

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Daily Digitals News journalist was involved in the writing and production of this article.

You may also like...